September 8, 2025

Microbot’s Liberty Endovascular Robotic System Cleared by FDA

September 8, 2025—Microbot Medical Inc. announced FDA 510(k) clearance was granted for the single-use, remotely operated Liberty endovascular robotic system for peripheral endovascular procedures.

According to the company, the Liberty pivotal study demonstrated 100% success in robotic navigation to the target and zero device-related adverse events. The study also showed a 92% relative reduction in radiation exposure for physicians. The company announced in April that findings from the ACCESS-PVI pivotal trial were presented by Francois Cornelis, MD, at SIR 2025.

Microbot stated that the device’s remote design is intended to improve ergonomics, which would aid in reducing the physical strain on health care providers. Additionally, the Liberty has the potential to enhance procedure efficiency, lower procedure costs, and improve the overall quality of care.

Microbot plans to continue clinical data collection for Liberty during the commercial launch, noted the press release.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

September 8, 2025

Microbot’s Liberty Endovascular Robotic System Cleared by FDA

Current Issue

Keep In Touch